Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
暂无分享,去创建一个
M. Tamburini | D. Ferrigno | D Ferrigno | G Buccheri | G. Buccheri | M Tamburini | Marcello Tamburini
[1] A. Biggi,et al. Imaging lung cancer by scintigraphy with indium 111‐labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody F023C5 , 1992, Cancer.
[2] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[3] C. Conill,et al. Performance status assessment in cancer patients , 1990, Cancer.
[4] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[5] D. Ferrigno,et al. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer , 1993, Cancer.
[6] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[7] C. Conill,et al. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? , 1992, European journal of cancer.
[8] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[9] S. Capewell,et al. Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group. , 1990, Thorax.
[10] P. Ganz,et al. Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Weller,et al. International Histological Classification of Tumours , 1981 .
[12] D. Ferrigno,et al. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG) , 1994, European journal of cancer.
[13] Antonio Curcio,et al. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19‐9 , 1987, Cancer.
[14] S. Siegel,et al. Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.
[15] L. Laliberte,et al. The Karnofsky performance status scale: An examination of its reliability and validity in a research setting , 1984, Cancer.
[16] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .
[17] Emil Frei,et al. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .
[18] D. Cox. Regression Models and Life-Tables , 1972 .
[19] J. Aisner,et al. Performance status assessment among oncology patients: a review. , 1986, Cancer treatment reports.
[20] Colin M. MacLeod,et al. Evaluation of chemotherapeutic agents , 1949 .
[21] Max H. Myers,et al. Manual for Staging of Cancer , 1992 .
[22] R. Cellerino,et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C , 2004, Cancer Chemotherapy and Pharmacology.
[23] A. Biggi,et al. Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography. , 1993, Chest.
[24] P. Ganz,et al. Quality of life assessment. An independent prognostic variable for survival in lung cancer , 1991, Cancer.
[25] A. Curcio,et al. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma , 1986 .
[26] H. Hansen,et al. Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.
[27] D. Ferrigno,et al. Prognostic factors in lung cancer: tables and comments. , 1994, The European respiratory journal.